Then, because BTZ treatment increases proteasome expression, and NRF1 is a regulator of proteasome subunit gene expression, we investigated the contribution of NRF1 and DDI2 to this proteasome bounce-back response in MM. This evidence concerns the gene CASC3 and Miyoshi myopathy.